Ancient Chinese Herb Compound Gastrodin Reawakens Exhausted T Cells to Fight Leukemia

A compound drawn from one of the most storied plants in traditional Chinese medicine may hold unexpected power against a rare and aggressive blood cancer. In a study published in the journal Medical Oncology, researchers report that gastrodin, a small molecule extracted from the orchid Gastrodia elata, significantly improved immune function in a mouse model of erythroleukemia, a malignant disorder of red blood cell precursors that is often accompanied by profound immunosuppression. The work, led by Sha Cheng and Heng Luo of Guizhou Medical University together with colleagues, provides the first evidence that this natural product can strengthen splenic immune defenses in leukemia by reactivating a central signaling pathway that governs how T cells respond to threats.

Erythroleukemia is an uncommon subtype of acute myeloid leukemia in which malignant transformation occurs in cells committed to becoming red blood cells. Clinically, the disease is notorious not only for its aggressive course but also for the way it cripples the immune system. T cell dysfunction sits at the heart of that immunosuppression, leaving patients with weakened defenses against both the malignancy itself and opportunistic infections. The spleen, a key reservoir of immune cells, often becomes enlarged, or splenomegalic, as malignant cells infiltrate the organ and distort its architecture. Restoring normal immune activity in this compromised environment has long been a challenge, and the new study suggests that a molecule better known for protecting the brain may help do exactly that.

Gastrodin has a long pharmacological pedigree. Derived from Gastrodia elata, a plant used for centuries in Chinese medicine to treat headaches, dizziness and neurological complaints, the compound has been shown in modern research to possess neuroprotective, anti-inflammatory and immunomodulatory activities. Recent reviews have catalogued its effects across the central nervous system and beyond, and earlier preclinical work even found that gastrodin could enhance the migration of engineered chimeric antigen receptor T cells toward brain tumors. What had never been tested, however, was whether the molecule could meaningfully improve immune function in the setting of leukemia. The Guizhou team set out to answer that question using a well-established mouse model of erythroleukemia.

The results were striking. Mice treated with gastrodin showed a significant alleviation of splenomegaly, indicating that the drug eased the malignant expansion that distorts the spleen in this disease. Treatment also inhibited the overall malignant progression of erythroleukemia in the animals. Beyond these direct anti-leukemic effects, the researchers documented a measurable revival of immune competence: splenic T cells from gastrodin-treated mice displayed markedly enhanced proliferative capacity, meaning they could divide and expand far more vigorously than T cells from untreated leukemic animals. The compound also promoted the secretion of immune-related cytokines, the chemical messengers that coordinate antitumor responses and orchestrate communication between immune cell populations.

To understand how a simple plant-derived molecule could accomplish all this, the investigators turned their attention to the T cell receptor, or TCR, signaling pathway, the molecular circuit that translates recognition of a foreign antigen into T cell activation. When a T cell’s receptor engages its target, a cascade of intracellular events unfolds: the kinase LCK initiates the signal, ZAP-70 amplifies it, ITK and PKC propagate it downstream, and the IKK complex and the transcription factor NFκB carry the message into the nucleus, where genes governing proliferation, cytokine production and cell survival are switched on. In immunosuppressed leukemic hosts, this cascade is blunted, leaving T cells sluggish and unresponsive.

Gastrodin, the study found, reversed that blunting. The compound upregulated the expression of the key molecules in the TCR signaling pathway, including LCK, ZAP-70, ITK, PKC, IKK and NFκB, at both the messenger RNA level, measured by quantitative real-time polymerase chain reaction, and at the level of protein phosphorylation, detected by western blot analysis. Phosphorylation is the molecular switch that activates many of these signaling proteins, so the finding that gastrodin boosted phosphorylated forms of the pathway components indicates that the drug did not merely increase the abundance of the machinery but also energized its function. Immunohistochemistry was used to corroborate these changes within tissue, giving the team a multi-layered picture of pathway reactivation in the spleen.

The mechanistic story did not end there. Through integrated bioinformatics analysis, molecular docking simulations and cellular thermal shift assays, the researchers identified a surprising potential interaction partner: Fli-1, a transcription factor with a famous history in erythroleukemia research. Fli-1, a member of the ets gene family, was originally discovered as a common proviral integration site in erythroleukemia cells induced by the Friend murine leukemia virus, and decades of work have established its role in hematopoiesis and malignant transformation. The cellular thermal shift assay, a technique that detects whether a small molecule physically binds to and stabilizes a protein inside cells, indicated that gastrodin exhibits a moderate interaction with Fli-1 in erythroleukemia. The authors are careful to note that this physical interaction is only a first clue: the functional contribution of Fli-1 binding to the compound’s immune-enhancing effects remains to be further explored.

That caveat matters, but the Fli-1 connection is intriguing for reasons that extend beyond this single study. Prior research has shown that Fli-1 influences T cell behavior, including the regulation of thymocyte development and the enhancement of TCR signal strength during gamma-delta T cell commitment, and that reducing FLI1 levels in lupus-prone mice alters T cell function through metabolic changes. Other recent work has implicated FLI1 in tumor immune evasion, showing that the transcription factor promotes interferon-gamma-induced kynurenine production that impairs antitumor immunity. A natural molecule that physically engages Fli-1 while simultaneously reviving TCR signaling therefore opens several testable hypotheses about how the compound might be rewiring the leukemic immune microenvironment, whether through direct transcriptional effects or through the downstream amplification of T cell activation circuits.

The study’s methodology reflects a modern, multi-pronged approach to natural product pharmacology. Animal experiments, approved by the Animal Ethics Committee of Guizhou Medical University, established the therapeutic effects in vivo. Molecular biology techniques, including qRT-PCR, western blotting and immunohistochemistry, mapped the signaling changes. Bioinformatics and molecular docking then narrowed the field of candidate protein targets, and the cellular thermal shift assay provided biophysical evidence of a drug-protein interaction. The work was supported by the National Natural Science Foundation of China and several Guizhou provincial funding programs, and the authors report no competing interests. The team included researchers from Guizhou Medical University’s State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, the Natural Products Research Center of Guizhou Province, Baiyun Affiliated Hospital of Guizhou Medical University and Guizhou Wansheng Pharmaceutical.

For the field, the implications are twofold. First, the findings position gastrodin as a promising immunotherapeutic candidate for erythroleukemia, a disease in which treatment options remain limited and immune restoration is an unmet need. Because gastrodin has a long history of human use in traditional medicine and a favorable safety profile in prior pharmacological studies, the path from a mouse model toward translational exploration may be shorter than for entirely novel synthetic compounds. Second, the study adds to a growing body of evidence that natural small molecules can modulate core immune signaling pathways in cancer, complementing approaches such as immune checkpoint inhibitors and adoptive T cell therapies that dominate current immunotherapy. Whether gastrodin can deliver comparable benefits in human patients, at what dose, and with what long-term consequences are questions that will require further preclinical development and, eventually, clinical testing. The Fli-1 interaction, in particular, awaits functional validation. But as a first demonstration that a centuries-old herbal compound can switch T cell receptor signaling back on in a leukemic spleen, the study offers a compelling proof of concept that the boundary between traditional pharmacology and modern cancer immunotherapy is thinner than many might assume.

Subject of Research: The immunomodulatory effects of gastrodin on splenic T-cell immunity in erythroleukemia through regulation of the T-cell receptor signaling pathway.

Article Title: Gastrodin enhances the spleen immune function in erythroleukemia by regulating T-cell receptor signaling pathway

Article References: Cheng, S., Xu, Y., Wang, J., Yu, J., Hu, L., Liu, J., & Luo, H. (2026). Gastrodin enhances the spleen immune function in erythroleukemia by regulating T-cell receptor signaling pathway. Medical Oncology, 43(10), Article 291. https://doi.org/10.1007/s12032-026-03388-2

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03388-2

Keywords: gastrodin, erythroleukemia, T-cell receptor signaling, Fli-1, spleen immune function, Gastrodia elata, immunotherapy, leukemia, NF-kB, cytokines, molecular docking, natural products